Home › Therapeutic areas › Renal › Lupus Nephritis
Lupus Nephritis (11 companies)
Companies with an active program in Lupus Nephritis.
| Ticker | Company | Therapeutic areas | Programs | Lead stage | Mkt cap | Programs |
|---|---|---|---|---|---|---|
| ACET | Adicet Bio | ImmunologyNeurology+2 Rare | 1 | Phase 1 | $28.6M | 8 |
| AKBA | Akebia Therapeutics | HematologyOphthalmology+2 Rare | 1 | Approved | $111M | 10 |
| ANNX | Annexon | HematologyNeurology+2 Rare | 1 | Phase 3 | $796M | 6 |
| AUTL | Autolus Therapeutics | HematologyImmunology+3 Rare | 1 | Approved | $341M | 12 |
| CABA | Cabaletta Bio | DermatologyImmunology+2 Rare | 1 | Phase 2 | $280M | 8 |
| IPSC | Century Therapeutics | ImmunologyMetabolic+1 Rare | 2 | Phase 1 | $304M | 9 |
| CGEM | Cullinan Therapeutics | HematologyImmunology+2 Rare | 1 | NDA Submitted | $728M | 10 |
| FATE | Fate Therapeutics | ImmunologyOncology+1 Rare | 1 | Phase 2 | $224M | 10 |
| KYTX | Kyverna Therapeutics | ImmunologyNeurology+1 Rare | 1 | NDA Submitted | $302M | 7 |
| NKTX | Nkarta | ImmunologyNeurology+1 Rare | 1 | Phase 1 | $124M | 8 |
| NVCT | Nuvectis Pharma | HematologyOncology+1 Rare | 1 | Phase 3 | $719M | 9 |
No companies match.